Physician profile
Mark S Currie
NPI 1700862273
$12,482.17
in general payments reported to CMS, 2019-2025
82 companies · $677 in 2025
The $677 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,072 · 2020: $529 · 2021: $1,759 · 2022: $2,263 · 2023: $2,517 · 2024: $2,665 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,700 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,699.74 |
| Education | $159.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $798.44 | 2019-2025 | |
| Janssen Biotech, INC. | $747.37 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Genentech USA, INC. | $732.32 | 2019-2024 | Tecentriq, Avastin, Rozlytrek |
| Astrazeneca Pharmaceuticals Lp | $631.46 | 2019-2024 | Calquence, Lynparza, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $585.09 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Pfizer INC. | $580.67 | 2019-2024 | |
| Astellas Pharma US INC | $572.74 | 2019-2025 | Padcev, Xospata, Xtandi |
| Celgene Corporation | $537.71 | 2019-2024 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $469.11 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $399.45 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $365.40 | 2019-2023 | Xgeva, Nplate, Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $353.72 | 2019-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $303.84 | 2020-2024 | Enhertu |
| Genzyme Corporation | $297.43 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $296.64 | 2019-2025 |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $290.27 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $289.93 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Ipsen Biopharmaceuticals, INC | $211.68 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| Lilly USA, LLC | $206.23 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $197.17 | 2019-2025 | Venclexta |
| Taiho Oncology, INC. | $196.58 | 2021-2025 | |
| Seagen INC. | $191.32 | 2019-2023 | Tukysa, Padcev |
| Puma Biotechnology, INC. | $169.50 | 2019-2024 | Nerlynx |
| Alexion Pharmaceuticals, INC. | $166.77 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $139.56 | 2019-2025 | Ojjaara, Shingrix |
| Gilead Sciences, INC. | $134.93 | 2019-2024 | Trodelvy |
| Karyopharm Therapeutics INC. | $121.24 | 2021-2024 | Xpovio |
| Blue Earth Diagnostics | $116.66 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $82.10 | 2021-2024 | |
| Mirati Therapeutics, INC. | $79.95 | 2023-2024 | Krazati |
| Myovant Sciences INC. | $79.17 | 2021-2022 | |
| Blueprint Medicines Corporation | $79.14 | 2021-2025 | Ayvakit |
| Alnylam Pharmaceuticals INC. | $77.21 | 2022-2024 | Givlaari |
| Rigel Pharmaceuticals, INC. | $70.89 | 2019-2024 | Rezlidhia, Tavalisse |
| Janssen Pharmaceuticals, INC | $69.88 | 2019-2023 | Xarelto |
| Emd Serono, INC. | $68.70 | 2019-2024 | Bavencio |
| Exelixis INC. | $67.24 | 2019-2024 | Cabometyx |
| Array Biopharma INC | $66.92 | 2021-2023 | Xalkori, Braftovi, Mektovi |
| Coherus Oncology, INC. | $66.49 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $63.58 | 2023-2024 | Orgovyx |
| Jazz Pharmaceuticals INC. | $62.27 | 2022-2025 | |
| Adc Therapeutics America, INC. | $60.56 | 2021-2024 | |
| Kite Pharma, INC. | $60.55 | 2023 | Yescarta |
| Genmab U.S., INC. | $59.41 | 2023-2024 | Epkinly |
| Tesaro, INC. | $58.38 | 2019 | |
| Aveo Pharmaceuticals, INC. | $57.89 | 2021-2024 | |
| Fennec Pharmaceuticals, INC. | $56.86 | 2025 | Fyarro |
| Pharmacosmos Therapeutics INC. | $56.60 | 2023-2024 | Monoferric |
| Tactile Systems Technology INC | $56.17 | 2022 | |
| Dendreon Pharmaceuticals LLC | $55.71 | 2024-2025 | Provenge |
| G1 Therapeutics, INC. | $54.22 | 2022-2023 | Cosela |
| Novocure INC. | $52.58 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Pharmaessentia USA Corporation | $51.91 | 2023 | Besremi |
| Tersera Therapeutics LLC | $46.47 | 2023-2024 | Xermelo |
| Beigene USA, INC. | $42.31 | 2024 | Brukinsa |
| Foundation Medicine, INC. | $42.02 | 2019 | |
| Sobi, INC | $40.54 | 2022 | |
| Morphosys, US INC. | $35.72 | 2021-2023 | Monjuvi |
| Kyowa Kirin, INC. | $34.03 | 2019 | |
| Agios Pharmaceuticals, INC. | $32.75 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $30.29 | 2024 | Clonoseq |
| Clovis Oncology, INC. | $29.79 | 2019-2021 | |
| Ge Healthcare | $28.58 | 2022 | |
| Stemline Therapeutics INC. | $28.26 | 2024 | Orserdu |
| Biocon Biologics INC | $26.46 | 2023 | Fulphila |
| Ucb, INC. | $24.67 | 2023 | |
| Springworks Therapeutics, INC. | $24.53 | 2024 | Ogsiveo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.70 | 2019 | |
| Apellis Pharmaceuticals, INC. | $22.56 | 2023 | Empaveli |
| Spectrum Pharmaceuticals INC. | $21.91 | 2024 | Rolvedon |
| Dova Pharmaceuticals | $21.57 | 2019 | |
| Legend Biotech USA INC. | $21.12 | 2025 | Carvykti |
| Epizyme, INC. | $20.02 | 2021 | |
| Progenics Pharmaceuticals, INC. | $19.98 | 2024 | |
| Pharming Healthcare, INC. | $19.89 | 2023 | Ruconest |
| Organon LLC | $19.74 | 2022 | |
| Cti Biopharma Corp. | $19.66 | 2023 | Vonjo |
| Sanofi-Aventis U.S. LLC | $18.71 | 2019 | |
| Myriad Genetic Laboratories, INC. | $18.20 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.07 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $17.06 | 2022 | |
| Verastem, INC. | $15.95 | 2019 |
Drugs and devices associated with these payments
Darzalex $257Lenvima $209Enhertu $185Jakafi $174Imbruvica $156Keytruda $152Lynparza $135Opdivo $134Tecentriq $131Venclexta $127Ultomiris $126Padcev $124Lonsurf $123Inqovi $123Verzenio $119Nubeqa $113Tecvayli $111Orgovyx $109Xtandi $108Avastin $107Jaypirca $102Kisqali $102Retevmo $97.28Epkinly $94.78Sarclisa $92.65Xpovio $89.01Monjuvi $84.06Onivyde $82.38Rozlytrek $82.02Alecensa $82.02Krazati $79.95Vitrakvi $75.11Stivarga $75.11Ibrance $73.16Enjaymo $72.66Elrexfio $67.88Calquence $67.73Tazverik $66.99Reblozyl $66.57Tukysa $64.99Bosulif $61.66Pomalyst $58.40Ninlaro $58.22Givlaari $58.02Fyarro $56.86Monoferric $56.60Provenge $55.71Cabometyx $54.36Besremi $51.91Talvey $51.54Adcetris $50.92Opdualag $50.21Xospata $48.32Talzenna $48.03Eliquis $47.67Xermelo $46.47Rybrevant $46.39Fabhalta $46.13Ayvakit $45.96Polivy $43.13Columvi $43.13Lunsumio $43.13Brukinsa $42.31Tibsovo $42.03Rezlidhia $41.96Tavalisse $41.96Posluma $40.84Besponsa $40.10Pemazyre $39.81Tagrisso $39.75Zepzelca $39.72Cosela $35.57Itovebi $31.80Akeega $31.66Erleada $31.66Balversa $31.66Fruzaqla $30.92Clonoseq $30.29Xofigo $29.15Trodelvy $28.79Orserdu $28.26Yescarta $27.92Iclusig $27.30Ojjaara $26.72Optune $26.62Fulphila $26.46Optune Lua (Novottf-200t) $25.96Loqtorzi $25.58Pluvicto $25.44Vyloy $25.21Ogsiveo $24.53Tecentriq Hybreza $24.20Perjeta $23.38Phesgo $23.38Nplate $23.36Xgeva $23.36Empaveli $22.56Axumin $22.53Comirnaty $22.41Inlyta $22.41
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Currie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.